Pathogenesis and management of osteoporosis in thalassemia

Pediatric Endocrinology Reviews

Volumn 6, Issue SUPPL. 1, 2008, Pages 86-93

  Voskaridou, Ersi ^a   Terpos, Evangelos ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b 251 GENERAL AIR FORCE HOSPITAL   (Greece)

Author keywords

Bisphosphonates; Osteoporosis; Pathogenesis; Thalassemia; Therapy

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; CALCIUM; CHORIONIC GONADOTROPIN; CLODRONIC ACID; COLECALCIFEROL; DEFEROXAMINE; ESTROGEN; HEMOGLOBIN; HYDROXYUREA; IRON CHELATING AGENT; PAMIDRONIC ACID; PLACEBO; SOMATOMEDIN; VITAMIN D; ZOLEDRONIC ACID;

ARTICLE; BONE DENSITY; BONE MARROW; BONE NECROSIS; BONE TURNOVER; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE DEFICIENCY; HEMATOPOIESIS; HEREDITY; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; HYPOTHYROIDISM; IRON OVERLOAD; JAW DISEASE; OSTEOBLAST; OSTEOLYSIS; OSTEOPENIA; OSTEOPOROSIS; PARATHYROID DISEASE; PATHOGENESIS; PHYSICAL ACTIVITY; THALASSEMIA; VITAMIN DEFICIENCY;

BETA-THALASSEMIA; HUMANS; OSTEOPOROSIS;

EID: 58149490842     PISSN: 15654753     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (92)

1. Pootrakul P, Hungsprenges S, Fucharoen S, Baylink D, Thompson E, English E, Lee M, Burnell J, Finch C. Relation between erythropoiesis and bone metabolism in thalassemia. New Engl J Med 1981;304:1470-1473
2. Michelson J, Cohen A. Incidence and treatment of fractures in thalassemia. J Orthop Trauma 1988;2:29-32
3. Johanson NA. Musculoskeletal problems in hemoglobinopathy. Orthop Clin North Am 1990;21:191-198
4. Orvieto R, Leichter I, Rachmilewitz EA, Margulies JY. Bone density, mineral content, and cortical index in patients with thalassemia major and the correlation to their bone fractures, blood transfusions, and treatment with desferrioxamine. Calcif Tissue Int 1992;50:397-399
5. Jensen CE, Tuck SM, Agnew JE, Koneru S, Morris RW, Yardumian A, Prescott E, Hoffbrand AV, Wonke B. High prevalence of low bone mass in thalassaemia major. Br J Haematol 1998;103:911-915
6. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann NY Acad Sci 1998;850:344-348
7. Giardina PJ, Schneider R, Lesser M, Simmons B, Rodriguez A, Gertner J, New M, Hilgartner MW. Abnormal bone metabolism in thalassaemia. In: Ando S et al. editors. Endocrine Disorders in Thalassaemia. Berlin: Springer; 1995 pp. 39-46
8. Abdollah Shamshirsaz A, Bekheirnia MR, Kamgar M, Pourzahedgilani N, Bouzari N, Habibzadeh M, Hashemi R, Abdollah Shamshirsaz AH, Aghakhani S, Homayoun H, Larijani B. Metabolic and endocrinologic complications in beta-thalassemia major: a multicenter study in Tehran. BMC Endocr Disord 2003;3:1-6
9. de Vernejoul MC, Girot R, Gueris J, Cancela L, Bang S, Bielakoff J, Mautalen C, Goldberg D, Miravet L. Calcium phosphate metabolism and bone disease in patients with homozygous thalassemia. J Clin Endocrinol Metab 1982;54:276-281
10. Voskaridou E, Terpos E. New insights into the pathophysiology and management of osteoporosis in patients with beta thalassaemia. Br J Haematol 2004;127:127-139
11. Jensen CE, Tuck SM, Old J, Morris RW, Yardumian A, De Sanctis V, Hoffbrand AV, Wonke B. Incidence of endocrine complications and clinical disease severity related to genotype analysis and iron overload in patients with beta-thalassaemia. Eur J Haematol 1997;59:76-81
12. Garofalo F, Piga A, Lala R, Chiabotto S, Di Stefano MM, Isaia GC. Bone metabolism in thalassemia. Ann N Y Acad Sci 1998;850:475-478
13. Wonke B, Jensen C, Hanslip JJ, Prescott, Lalloz M, Layton M, Erten S, Tuck S, Agnew JE, Raja K, Davies K, Hoffbrand AV. Genetic and acquired predisposing factors and treatment of osteoporosis in thalassaemia major. J Pediatr Endocrinol Metab 1998;11:(Suppl 3):795-801
14. Piga A, Luzzatto L, Capalbo P, Gambotto S, Tricta F, Gabutti V. High-dose desferrioxamine as a cause of growth failure in thalassemic patients. Eur J Haematol 1988;40:380-381 (letter)
15. Brill PW, Winchester P, Giardina PJ, Cunningham-Rundles S. Deferoxamine-induced bone dysplasia in patients with thalassemia major. Am J Roentgenol 1991;156:561-565
16. Rodda CP, Reid ED, Johnson S, Doery J, Matthews R, Bowden DK. Short stature in homozygous beta-thalassaemia is due to disproportionate truncal shortening. Clin Endocrinol 1995;42:587-592
17. Hatori M, Sparkman J, Teixeira CC, Grynpas M, Nervina J, Olivieri N, Shapiro IM. Effects of deferoximine on chondrocyte alkaline phosphatase activity: proxidant role of deferoximine in thalassemia. Calcif Tissue Int 1995;57:229-236
18. Olivieri NF. The beta-thalassemias. N Engl J Med 1999;341:99-109
19. Di Stefano M, Chiabotto P, Roggia C, Garofalo F, Lata R, Piga A, Isaia GC. Bone mass and metabolism in thalassemic children and adolescents treated with different iron-chelating drugs. J Bone Miner Metab 2004;22:53-57
20. Lasco A, Morabito N, Gaudio A, Buemi M, Wasniewska M & Frisina N. Effects of hormonal replacement therapy on bone metabolism in young adults with beta-thalassemia major. Osteoporos Int 2001;12:570-575
21. Carmina E, Di Fede G, Napoli N, Renda G, Vitale G, Lo Pinto C, Bruno D, Malizia R, Rini GB. Hypogonadism and hormone replacement therapy on bone mass of adult women with thalassemia major. Calcif Tissue Int 2004;74:68-71
22. Uitterlinden AG, Weel AE, Burger H, Fang Y, van Duijn CM, Hofman A, van Leeuwen JP, Pols HA. Interaction between the vitamin D receptor gene and coltagen type I alpha 1 gene in susceptibility for fracture. J Bone Miner Res 2001;16:379-385
23. Byers PH, Steiner RD. Osteogenesis imperfecta. Annu Rev Med 1992;43:269-282
24. Uitterlinden AG, Burger H, van Duijn CM, Huang Q, Hofman A, Birkenhager JC, van Leeuwen JP, Pols HA. Adjacent genes, for COL2A1 and the vitamin D receptor, are associated with separate features of radiographic osteoarthritis of the knee. Arthritis Rheum 2000;43:1456-1464
25. Perrotta S, Cappellini MD, Bertoldo F, Servedio V, Iolascon G, D'Agruma L, Gasparini P, Siciliani MC, Iolascon A. Osteoporosis in beta-thalassaemia major patients: analysis of the genetic background. Br J Haematol 2000;111:461-466
26. Dresner Pollack R, Rachmilewitz E, Blumenfeld A, Idelson M, Goldfarb AW. Bone mineral metabolism in adults with beta-thalassaemia major and intermedia. Br J Haematol 2000;111:902-907
27. Uitterlinden AG, Fang Y, Bergink AF, van Meurs JB, van Leeuwen HP, Pols HA. The role of vitamin D receptor gene polymorphisms in bone biology. Mol Cell Endocrinol 2002;197:15-21
28. Ferrara M, Matarese S, Francese M, Borrelli B, Coppola A, Coppola L, Esposito L. Effect of VDR polymorphisms on growth and bone mineral density in homozygous beta thalassaemia. Br J Haematol 2002;117:436-440
29. Malloy PJ, Weisman Y, Feldman D. Hereditary 1 alpha, 25-dihydroxyvitamin D-resistant rickets resulting from a mutation in the vitamin D receptor deoxyribonucleic acid-binding domain. J Clin Endocrinol Metab 1994;78:313-316
30. Morrison NA, Qi JC, Tokita A, Kelly PJ, Crofts L, Nguyen TV, Sambrook PN, Eisman JA. Prediction of bone density from vitamin D receptor alleles. Nature 1994;367:284-287
31. Cooper GS, Umbach DM. Are vitamin D receptor polymorphisms associated with bone mineral density? A meta-analysis. J Bone Miner Res 1996;11:1841-1849
32. Langdahl BL, Knudsen JY, Jensen HK, Gregersen N, Eriksen EF. A sequence variation: 713-8delC in the transforming growth factor-beta 1 gene has higher prevalence in osteoporotic women than in normal women and is associated with very low bone mass in osteoporotic women and increased bone turnover in both osteoporotic and normal women. Bone 1997;20:289-294
33. Bertoldo F, D'Agruma L, Furlan F, Colapietro F, Lorenzi MT, Maiorano N, Iolascon A, Zelante L, Locascio V, Gasparini P. Transforming growth factor-beta1 gene polymorphism, bone turnover, and bone mass in Italian postmenopausal women. J Bone Miner Res 2000;15:634-639
34. Masi L, Becherini L, Colli E, Gennari L, Mansani R, Falchetti A, Becorpi AM, Cepollaro C, Gonnelli S, Tanini A, Brandi ML. Polymorphisms of the calcitonin receptor gene are associated with bone mineral density in postmenopausal Italian women. Biochem Biophys Res Commun 1998;248:190-195
35. Smith EP, Boyd J, Frank GR, Takahashi H, Cohen RM, Specker B, Williams TC, Lubahn DB, Korach KS. Estrogen resistance caused by a mutation in the estrogen-receptor gene in a man. N Engl J Med 1994;331:1056-1061
36. Han KO, Moon IG, Kang YS, Chung HY, Min HK, Han IK. Nonassociation of estrogen receptor genotypes with bone mineral density and estrogen responsiveness to hormone replacement therapy in Korean postmenopausal women. J Clin Endocrinol Metab 1997;82:991-995
37. Anapliotou ML, Kastanias IT, Psara P, Evangelou EA, Liparaki M, Dimitriou P. The contribution of hypogonadism to the development of osteoporosis in thalassaemia major: new therapeutic approaches. Clin Endocrinol 1995;42:279-287
38. Raiola, G, Galati MC, De Sanctis V, Caruso Nicoletti M, Pintor C, De Simone M, Arcuri VM, Anastasi S. Growth and puberty in thalassemia major. J Pediatr Endocrinol Metab 2003;16(Suppl 2):259-266
39. Wonke B. Clinical management of beta-thalassemia major. Semin Hematol 2001;38:350-359
40. Olivieri NF, Koren G, Harris J, Khattak S, Freedman MH, Templeton DM, Bailey JD, Reilly BJ. Growth failure and bony changes induced by deferoxamine. Am J Pediatr Hematol Oncol 1992;14:48-56
41. De Sanctis V, Pinamonti A, Di Palma A, Sprocati M, Atti G, Gamberini MR, Vullo C. Growth and development in thalassaemia major patients with severe bone lesions due to desferrioxamine. Eur J Pediatr 1996;155:368-372
42. Lata R, Chiabotto P, Di Stefano M, Isaia GC, Garofalo F, Piga A. Bone density and metabolism in thalassaemia. J Pediatr Endocrinol Metab 1998;11(Suppl 3):785-790
43. Chan YL, Pang LM, Chik KW, Cheng JC, Li CK. Patterns of bone diseases in transfusion-dependent homozygous thalassaemia major: predominance of osteoporosis and desferrioxamine-induced bone dysplasia. Pediatr Radiol 2002;32:492-497
44. De Sanctis V, Stea S, Savarino L, Scialpi V, Traina GC, Chiarelli GM, Sprocati M, Govoni R, Pezzoli D, Gamberini R, Rigolin F. Growth hormone secretion and bone histomorphometric study in thalassaemic patients with acquired skeletal dysplasia secondary to desferrioxamine. J Pediatr Endocrinol Metab 1998;11(Suppl 3):827-833
45. Mahachoklertwattana P, Chuansumrit A, Sirisriro R, Choubtum L, Sriphrapradang A, Rajatanavin R. Bone mineral density, biochemical and hormonal profiles in suboptimatly treated children and adolescents with beta-thalassaemia disease. Clin Endocrinol 2003;58:273-279
46. World Health Organization. Assessment of fracture risks and its application to screening for post-menopausal osteoporosis. Report of a WHO Study Group. World Health Organ Tech Rep Ser 1994;843:1-129
47. Bonjour JP, Ammann P, Rizzoli R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos Int 1999;9:379-393
48. Nguyen TV, Pocock N, Eisman JA. Interpretation of bone mineral density measurement and its change. J Clin Densitom 2000;3:107-119
49. Binkley NC, Schmeer P, Wasnich RD, Lenchik L. What are the criteria by which a densitometric diagnosis of osteoporosis can be made in males and non-Caucasians? J Clin Densitom 2002;5:19-27
50. Berkovitch M, Bistritzer T, Milone SD, Perlman K, Kucharczyk W, Olivieri NF. Iron deposition in the anterior pituitary in homozygous beta-thalassemia: MRI evaluation and correlation with gonadal function. J Pediatr Endocrinol Metab 2000;13:179-184
51. Riggs BL, Khosla S, Melton LJ 3rd. A unitary model for involutional osteoporosis: estrogen deficiency causes both type I and type II osteoporosis in postmenopausal women and contributes to bone loss in aging men. J Bone Miner Res 1998;13:763-773
52. Riggs BL. The mechanisms of estrogen regulation of bone resorption. J Clin Invest 2000;106:1203-1204
53. Olszynski WP, Shawn Davison K, Adachi JD, Brown JP, Cummings SR, Hanley DA, Harris SP, Hodsman AB, Kendler D, McClung MR, Miller PD, Yuen CK. Osteoporosis in men: epidemiology, diagnosis, prevention, and treatment. Clin Ther 2004;26:15-28
54. Geusens PP, Boonen S. Osteoporosis and the growth hormone-insulin-like growth factor axis. Horm Res 2002;58(Suppl 3):49-55
55. Rucker D, Ezzat S, Diamandi A, Khosravi J, Hanley DA. IGF-I and testosterone levels as predictors of bone mineral density in healthy, community-dwelling men. Clin Endocrinol 2004;60:491-499
56. Soliman AT, El Banna N, Abdel Fattah M, El Zalabani MM, Ansari BM. Bone mineral density in prepubertal children with beta-thalassemia: correlation with growth and hormonal data. Metabolism 1998;47:541-548
57. Lasco A, Morabito N, Gaudio A, Crisafulli A, Meo A, Denuzzo G, Frisina N. Osteoporosis and beta-thalassemia major: role of the IGF-I/IGFBP-III axis. J Endocrinol Invest 2002;25:338-344
58. Perifanis V, Vyzantiadis T, Vakalopoulou, S, Tziomalos K, Garypidou V, Athanassiou-Metaxa M, Harsoulis F. Treatment of beta-thalassaemia-associated osteoporosis with zoledronic acid. Br J Haematol 2004;125:91-92
59. Morabito N, Gaudio A, Lasco A, Atteritano M, Pizzoleo MA, Cincotta M, La Rosa M, Guarino R, Meo A, Frisina N. Osteoprotegerin and RANKL in the pathogenesis of thalassemia-induced osteoporosis: new pieces of the puzzle. J Bone Miner Res 2004;19:722-727
60. Mahachoklertwattana P, Srikulchayanonta V, Chuansumrit A, Karnsombat, P, Choubtum L, Sriphrapradang A, Domrongkitchaiporn S, Sirisriro R, Rajatanavin R. Bone histomorphometry in children and adolescents with beta-thalassemia disease: iron-associated focal osteomalacia. J Clin Endocrinol Metab 2003;88:3966-3972
61. Vichinsky EP. The morbidity of bone disease in thalassemia. Ann NY Acad Sci 1998;850:344-348
62. Ma ES, Lam KK, Chan AY, Ha SY, Au WY, Chan LC. Transferrin receptor-2 polymorphisms and iron overload in transfusion independent b-thalassemia intermedia. Haematologica 2003;88:345-346
63. Michelson J, Cohen A. Incidence and treatment of fractures in thalassemia. J Orthop Trauma 1988;2:29-32
64. Johnston CC. Jr, Miller JZ, Slemenda CW, Reister TK, Hui S, Christian JC, Peacock M. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-87
65. Whedon GD. Disuse osteoporosis: physiological aspects. Calcif Tissue Int 1984;36(Suppl 1):146-150
66. Todd JA, Robinson RJ. Osteoporosis and exercise. Postgrad Med J 2003;79:320-323
67. Lane NE, Bloch DA, Jones HH, Marshall WH Jr, Wood PD, Fries JF. Long-distance running, bone density, and osteoarthritis. JAMA 1986;255:1147-1151
68. Lindsay R. Prevention and treatment of osteoporosis. Lancet 1993;341:801-805
69. Canatan D, Akar N, Arcasoy A. Effects of calcitonin therapy on osteoporosis in patients with thalassemia. Acta Haematol 1995;93:20-24
70. Angastiniotis M, Pavlides N, Aristidou K, Kanakas A, Yerakaris M, Eracleous E, Posporis T. Bone pain in thalassaemia: assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab 1998;11(Suppl 3):779-784
71. Kosarvan M, Zadeh MF, Shahi VK. The bone density of thalassemic patients of Boo Ali Sina hospital, Sari, Iran in 2002; does hydroxyurea help? Pediatr Endocrinol Rev 2004;(Suppl 2):303-308
72. Suda T, Nakamura I, Jimi E, Takahashi N. Regulation of osteoclast function. J Bone Miner Res 1997;12:869-879
73. Fleisch H. Bisphosphonates: mechanisms of action. Endocrinol Rev 1998;19:80-100
74. Lin JH. Bisphosphonates: a review of their pharmacokinetic properties. Bone 1996;18:75-85
75. Terpos E, Rahemtulia A. Bisphosphonate treatment for multiple myeloma. Drugs Today 2004;40:29-40
76. Meunier PJ, Delmas PD, Eastell R, McClung MR, Papapoulos S, Rizzoli R, Seeman E, Wasnich RD. Diagnosis and management of osteoporosis in postmenopausal women: clinical guidelines. International Committee for Osteoporosis Clinical Guidelines. Clin Ther 1999;21:1025-1044
77. Morabito N, Lasco A, Gaudio A, Crisafulli A, Di Pietro C, Meo A, Frisina N. Bisphosphonates in the treatment of thalassemia-induced osteoporosis. Osteoporos Int 2002;13:644-649
78. Pennisi P, Pizzarelli G, Spina M, Riccobene S, Fiore CE. Quantitative ultrasound of bone and clodronate effects in thalassemia-induced osteoporosis. J Bone Miner Metab 2003;21:402-408
79. Voskaridou E, Terpos E, Spina G, Palermos J, Rahemtulla A, Loutradi A, Loukopoulos D. Pamidronate is an effective treatment for osteoporosis in patients with beta-thalassaemia. Br J Haematol 2003;123:730-773
80. Perifanis V, Vyzantiadis T, Tziomalos K, Vakalopoulou S, Garipidou V, Athanassiou-Metaxa M, Harsoulis F. Effect of zoledronic acid on markers of bone turnover and mineral density in osteoporotic patients with beta-thalassaemia. Ann Hematol 2007;86:23-30
81. Otrock ZK, Azar ST, Shamsedden WA, Habr D, Inati A, Koussa S, Mahfouz RA, Taher AT. Intravenous zoledronic acid treatment in thalassemia-induced osteoporosis: results of a phase II clinical trial. Ann Hematol 2006;9:605-660
82. Mahachoklertwattana P. Zoledronic acid for the treatment of thalassemia-induced osteoporosis. Haematologica 2006;91:1155
83. Voskaridou E, Anagnostopoulos A, Konstantopoulos K, Stoupa E, Spyropoulou E, Kiamouris C, Terpos E. Zoledronic acid for the treatment of osteoporosis in patients with beta-thalassemia: results from a single-center, randomized, placebo-controlied trial. Haematologica 2006;91:1193-1202
84. Woo SB, Hande K, Richardson PG. Osteonecrosis of the jaw and bisphosphonates. N Engl L Med 2005;353:99-102
85. Voskaridou E, Christoulas D, Konstantinidou M, Tsiftsakis E, Spyropoulou E, Alexakos P, Terpos E. Continuous improvement of bone mineral density two years post zoledronic acid discontinuation in patients with thalassemia-induced osteoporosis: long-term follow up of a randomized, placebo-controlled trial. Haematologica 2008; in press
86. Rodan G, Reszka A, Golub E, Rizzoli R. Bone safety of long-term bisphosphonate treatment. Curr Med Res Opin 2004;20:1291-1300
87. Voskaridou E, Christoulas D, Antoniadou E, Terpos E. Continuous increase in erythropoietic activity despite the improvement in bone mineral density by zoledronic acid in patients with thalassemia induced osteoporosis. Acta Haematol 2008;119:40-44
88. Jiang Y, Zhao JJ, Mitlak BH, Wang O, Genant HK, Eriksen EF. Recombinant human parathyroid hormone (1-34) (teriparatide) improves both cortical and cancellous bone structure. J Bone Miner Res 2003;18:1932-1941
89. Meunier PJ, Roux C, Seeman E, Ortolani S, Badurski JE, Spector TD, Cannata J, Balogh A, Lemmel EM, Pors-Nielsen S, Rizzoli R, Genant HK, Reginster JY. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;50:459-468
90. Kostenuik PJ, Bolon B, Morony S, Daris M, Geng Z, Carter C, Sheng J. Gene therapy with human recombinant osteoprotegerin reverses established osteopenia in ovariectomized mice. Bone 2004;34:656-664
91. Body JJ, Greipp P, Coleman RE, Facon T, Geurs F, Fermand JP, Harousseau JL, Lipton A, Mariette X, Williams CD, Nakanishi A, Holloway D, Martin SW, Dunstan CR, Bekker PJ. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer 2003;97(Suppl 3):887-892
92. Lewiecki EM, Miller PD, McClung MR, Cohen SB, Bolognese MA, Liu Y, Wang A, Siddhanti S, Fitzpatrick LA. AMG 162 Bone Loss Study Group. Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. J Bone Miner Res 2007;22:1832-1841